KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Assets (2017 - 2025)

Moderna (MRNA) has disclosed Assets for 7 consecutive years, with $12.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Assets changed N/A to $12.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $12.1 billion, a N/A change, with the full-year FY2024 number at $14.1 billion, changed N/A from a year prior.
  • Assets was $12.1 billion for Q3 2025 at Moderna, down from $12.7 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $27.6 billion in Q1 2022 to a low of $12.1 billion in Q3 2025.
  • A 4-year average of $18.5 billion and a median of $16.2 billion in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: skyrocketed 513.97% in 2021, then increased 4.82% in 2022.
  • Moderna's Assets stood at $24.7 billion in 2021, then grew by 4.82% to $25.9 billion in 2022, then crashed by 45.31% to $14.1 billion in 2024, then fell by 14.19% to $12.1 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Assets are $12.1 billion (Q3 2025), $12.7 billion (Q1 2025), and $14.1 billion (Q4 2024).